JP2008501316A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501316A5
JP2008501316A5 JP2007509640A JP2007509640A JP2008501316A5 JP 2008501316 A5 JP2008501316 A5 JP 2008501316A5 JP 2007509640 A JP2007509640 A JP 2007509640A JP 2007509640 A JP2007509640 A JP 2007509640A JP 2008501316 A5 JP2008501316 A5 JP 2008501316A5
Authority
JP
Japan
Prior art keywords
lactobacillus
composition
isolated
cytoprotective compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007509640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/013646 external-priority patent/WO2005112976A2/en
Publication of JP2008501316A publication Critical patent/JP2008501316A/ja
Publication of JP2008501316A5 publication Critical patent/JP2008501316A5/ja
Abandoned legal-status Critical Current

Links

JP2007509640A 2004-04-20 2005-04-20 ラクトバシルスｇｇ由来プロバイオティック化合物及びそれらの使用 Abandoned JP2008501316A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56404904P 2004-04-20 2004-04-20
PCT/US2005/013646 WO2005112976A2 (en) 2004-04-20 2005-04-20 Probiotic compounds from lactobacillus gg and uses therefor

Publications (2)

Publication Number Publication Date
JP2008501316A JP2008501316A (ja) 2008-01-24
JP2008501316A5 true JP2008501316A5 (https=) 2009-01-22

Family

ID=35428847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007509640A Abandoned JP2008501316A (ja) 2004-04-20 2005-04-20 ラクトバシルスｇｇ由来プロバイオティック化合物及びそれらの使用

Country Status (6)

Country Link
US (1) US20070123460A1 (https=)
EP (1) EP1745142A4 (https=)
JP (1) JP2008501316A (https=)
CN (1) CN1997748A (https=)
CA (1) CA2563702A1 (https=)
WO (1) WO2005112976A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
EP1744767A4 (en) * 2004-04-20 2008-08-13 Univ Chicago THERAPEUTIC DELIVERY SYSTEM WITH PEG-LIKE CONNECTION WITH HIGH MOLECULAR WEIGHT
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
ATE512211T1 (de) 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
CN101273738B (zh) * 2007-03-28 2011-06-01 哈尔滨正方科技有限公司 在常温下保持高活菌数的调配型酸性乳饮料的制备方法
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
DK3061766T3 (da) * 2009-04-28 2020-03-16 Univ Vanderbilt Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
WO2011009848A2 (en) * 2009-07-20 2011-01-27 Bracco Spa Therapeutic use of probiotics
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP2295535A1 (en) * 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
US9730969B2 (en) 2015-11-06 2017-08-15 Mead Johnson Nutrition Company Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
US20180161381A1 (en) * 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions and methods for reducing the occurrence or severity of viral infections, bacterial infections and viral and bacterial co-infections
CN113925884B (zh) * 2020-06-29 2024-05-14 创百股份有限公司 后生元提取物用于促进皮肤再生与抗老化的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
AU2001260791B2 (en) * 2000-05-25 2006-11-09 Nederlandse Organisatie Voor Toegepastnatuurwetenschappelijk Onderzoek Tno Fructosyltransferases (inulosucrase and levansucrase) from lactobacillus reuteri
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Similar Documents

Publication Publication Date Title
JP2008501316A5 (https=)
CN113736695B (zh) 用于改善肠屏障功能的益生菌菌株及其应用
CN104144693A (zh) 用于治疗肝脏疾病和障碍的组合物和方法
KR101302315B1 (ko) 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물
CN112933115B (zh) Akkermansia muciniphila在治疗慢性胰腺炎方面的应用
JP2008538288A5 (https=)
CN108611295B (zh) 一种缓解内毒素感染的脆弱拟杆菌及其应用
Walia et al. Montelukast in pediatric asthma management
CN118497080A (zh) 一种发酵粘液乳杆菌及其在制备缓解溃疡性结肠炎产品中的应用
KR20240054338A (ko) 시아노 화합물, 이의 제조 방법 및 용도
EP2903608A1 (en) Esters of short chains fatty acids for use in the treatment of immunogenic disorders
CN112888448B (zh) 单形巨单胞菌在预防和/或治疗代谢性疾病中的用途
CN108578420B (zh) 木犀草苷在制备防治脓毒血症药物中的应用
TW202133882A (zh) 肽與多醣的新共軛物
WO2017155053A1 (ja) 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤
US20130065962A1 (en) Compounds For Use In The Treatment Of Diseases
CN111700918B (zh) 一种用于缓解酒精性肠道损伤的药品
JP4232866B2 (ja) 細胞障害抑制剤
CN113101283A (zh) 一种多苯环共轭分子在制备抗病毒药物中的用途及抗病毒药物
CN108641980B (zh) 一种缓解内毒素感染的卵形拟杆菌及其应用
JP2010523506A5 (https=)
AU2018446089A1 (en) Pharmaceutical use of anemoside B4 against acute gouty arthritis
WO2013177963A1 (zh) 注射用泮托拉唑钠冻干粉组合物及其制备方法
CN116473966A (zh) Sb-222200在抑制nlrp3炎症小体活化中的应用
CN103037860A (zh) 用于治疗炎症性疾病的吡咯烷取代的黄酮